Additional caution or monitoring may be appropriate in research settings involving: Pregnancy- or lactation-related research models, where limited safety data is available Active cancer-, tumor-, or abnormal proliferative research models, where NAD-related and metabolic-signaling pathways may influence cellular-signaling mechanisms Cardiovascular- or uncontrolled-hypertension research models, where metabolic-pathway modulation may influence cardiovascular-related biomarkers in some experimental settings Thyroid-related or endocrine research models, where metabolic-pathway investigations may influence endocrine-related observations Diabetes- or glucose-regulation research models, where insulin- and glucose-related pathways may warrant closer monitoring in experimental settings Moderate to severe hepatic- or renal-impairment research models, where compound metabolism or clearance mechanisms may be altered Autoimmune- or inflammatory-response research models, where immune-metabolic signaling pathways may influence inflammatory-related biomarkers or cytokine observations Research conditions, dosage ranges, administration frequency, protocol duration, and concurrent compounds may influence tolerability observations across experimental settings
Picardi PK, Calegari VC, Prada PO, Moraes JC, Araujo E, Marcondes MC, et al
The increased risk may relate to rapid weight loss, changes in gallbladder motility, or alterations in bile acid composition
You will also achieve better results if you use these products consistently
11:e70101 Creatine as a therapeutic target in Alzheimers disease Curr Dev Nutr
